Puma Biotechnology Inc
$ 8.91
9.73%
07 Aug - close price
- Market Cap 453,514,000 USD
- Current Price $ 8.91
- High / Low $ 9.40 / 8.12
- Stock P/E 18.56
- Book Value 2.52
- EPS 0.48
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.22 %
- 52 Week High 9.40
- 52 Week Low 3.71
About
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
Analyst Target Price
$5.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-29 | 2023-11-02 |
| Reported EPS | 0.16 | -0.04 | 0.26 | 0.21 | 0.12 | 0.06 | 0.43 | 0.45 | -0.05 | -0.05 | 0.26 | 0.17 |
| Estimated EPS | 0.06 | -0.13 | 0.19 | 0.09 | 0.08 | -0.02 | 0.14 | 0.38 | -0.1 | -0.15 | 0.3 | 0.14 |
| Surprise | 0.1 | 0.09 | 0.07 | 0.12 | 0.04 | 0.08 | 0.29 | 0.07 | 0.05 | 0.1 | -0.04 | 0.03 |
| Surprise Percentage | 166.6667% | 69.2308% | 36.8421% | 133.3333% | 50% | 400% | 207.1429% | 18.4211% | 50% | 66.6667% | -13.3333% | 21.4286% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PBYI
2026-08-08 03:40:57
Puma Biotechnology Inc (PBYI) currently holds an earnings forecast score of 6.00, placing it 130th out of 156 companies in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for PBYI, with a range from $2.00 to $7.00. The company's next quarter revenue is expected to be $57.50M, and analysts generally suggest a "Hold" rating for the stock.
2026-08-07 18:40:57
Puma Biotechnology announced its second quarter 2026 financial results, reporting increased revenue and net income driven by demand for NERLYNX. The company also raised its full-year 2026 guidance and provided updates on its clinical development programs for alisertib in various cancer treatments. Financial highlights include product revenue of $53.6 million for Q2 2026 and net income of $8.2 million.
2026-08-07 18:40:57
Puma Biotechnology, Inc. reported a 26% increase in NERLYNX bottle sales in Q2 2026, reaching a debt-free status, and raised its full-year revenue guidance to $205-$209 million. The company is strategically focusing on biomarker-driven patient selection for alisertib, increasing R&D investment for clinical trials, and actively pursuing business development opportunities while maintaining fiscal responsibility. Key risk factors include elevated gross-to-net adjustments and monitoring of U.S. trade policies.
2026-08-07 18:40:57
Puma Biotechnology (NASDAQ: PBYI) reported strong Q2 2026 results, with revenue of $56.5 million and GAAP net income of $8.2 million, driven by increased U.S. demand for NERLYNX. The company raised its full-year NERLYNX revenue outlook to $205 million–$209 million and net income to $17 million–$20 million. Puma also became debt-free and continues to advance its alisertib clinical trials for breast and small-cell lung cancer.
2026-08-07 05:12:11
Puma Biotechnology Inc. (PBYI) reported strong Q2 2026 results, becoming debt-free and raising its full-year revenue and net income guidance. The company saw significant growth in NERLYNX sales and is advancing its alisertib clinical program, planning for new Phase III trials in 2027. Despite a dip in new prescriptions and a lowered royalty guidance due to potential generic competition in China, the company remains confident in its financial position and future growth strategies.
2026-08-06 22:12:12
Puma Biotechnology (PBYI) exceeded Q2 2026 revenue and earnings estimates, reporting $56.5 million in revenue and $0.16 GAAP EPS, driven by strong NERLYNX sales. The company returned to profitability after a prior quarter loss and raised its full-year 2026 guidance for net product revenue and net income. Puma also announced it is now debt-free and plans to advance its experimental cancer drug alisertib through mid-stage studies.
